Insider Selling: Fluidigm Co. (NASDAQ:FLDM) Insider Sells $1,522,392.84 in Stock

Share on StockTwits

Fluidigm Co. (NASDAQ:FLDM) insider Levin Easterly Partners Llc sold 134,487 shares of the business’s stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $11.32, for a total transaction of $1,522,392.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Levin Easterly Partners Llc also recently made the following trade(s):

  • On Friday, July 19th, Levin Easterly Partners Llc sold 83,728 shares of Fluidigm stock. The shares were sold at an average price of $11.50, for a total transaction of $962,872.00.
  • On Friday, June 28th, Levin Easterly Partners Llc sold 157,349 shares of Fluidigm stock. The shares were sold at an average price of $12.30, for a total transaction of $1,935,392.70.
  • On Monday, July 1st, Levin Easterly Partners Llc sold 186,759 shares of Fluidigm stock. The shares were sold at an average price of $12.31, for a total transaction of $2,299,003.29.
  • On Tuesday, June 25th, Levin Easterly Partners Llc sold 217,148 shares of Fluidigm stock. The shares were sold at an average price of $12.28, for a total transaction of $2,666,577.44.

NASDAQ:FLDM opened at $11.49 on Monday. The business has a fifty day simple moving average of $12.12. The stock has a market capitalization of $793.04 million, a PE ratio of -14.36 and a beta of 2.15. The company has a debt-to-equity ratio of 0.30, a current ratio of 3.26 and a quick ratio of 2.86. Fluidigm Co. has a 1 year low of $5.50 and a 1 year high of $14.90.

Fluidigm (NASDAQ:FLDM) last released its quarterly earnings data on Thursday, May 2nd. The medical research company reported ($0.44) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.30). The business had revenue of $30.10 million during the quarter, compared to analysts’ expectations of $29.18 million. Fluidigm had a negative return on equity of 43.75% and a negative net margin of 60.45%. The company’s revenue for the quarter was up 19.4% compared to the same quarter last year. Sell-side analysts anticipate that Fluidigm Co. will post -0.5 EPS for the current fiscal year.

FLDM has been the topic of several recent research reports. BidaskClub cut shares of Westport Fuel Systems from a “buy” rating to a “hold” rating in a research note on Friday. Piper Jaffray Companies boosted their price objective on shares of Marvell Technology Group from $22.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, May 3rd. Zacks Investment Research raised shares of HB Fuller from a “sell” rating to a “hold” rating in a research note on Wednesday, July 3rd. Finally, ValuEngine cut shares of Welbilt from a “hold” rating to a “sell” rating in a research note on Wednesday, June 12th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Fluidigm has a consensus rating of “Buy” and a consensus target price of $14.75.

Large investors have recently added to or reduced their stakes in the business. Millennium Management LLC raised its position in Fluidigm by 171.1% in the fourth quarter. Millennium Management LLC now owns 932,996 shares of the medical research company’s stock worth $8,042,000 after acquiring an additional 588,862 shares in the last quarter. RTW Investments LP purchased a new position in Fluidigm in the fourth quarter worth $7,622,000. Prescott Group Capital Management L.L.C. purchased a new position in Fluidigm in the first quarter worth $611,000. Two Sigma Investments LP raised its position in Fluidigm by 110.7% in the fourth quarter. Two Sigma Investments LP now owns 485,800 shares of the medical research company’s stock worth $4,188,000 after acquiring an additional 255,244 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in Fluidigm by 6.8% in the fourth quarter. Bank of New York Mellon Corp now owns 458,681 shares of the medical research company’s stock worth $3,953,000 after acquiring an additional 29,310 shares in the last quarter. Hedge funds and other institutional investors own 92.64% of the company’s stock.

Fluidigm Company Profile

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.

Read More: How to Invest in an Index Fund

Insider Buying and Selling by Quarter for Fluidigm (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.